NCT00972673已完成1 期
Phase I Study of GW685698X-A Randomized, Double Blind, Placebo Controlled, Parallel-group, Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Dose From a Novel Dry Powder Device in Healthy Japanese Male Subjects.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- PD: serum cortisol
研究概览
简要总结
This is a randomized, double blind, placebo controlled, parallel-group, repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose from a novel dry powder device in healthy Japanese male subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 64 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Japanese healthy male subjects aged between 20 and 64 years of age inclusive. Healthy subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history, physical examination, laboratory studies, and other tests.
- •Body weight ≥ 50kg and BMI within the range 18.5-25.0kg/m2 inclusive.
- •Non-smokers (never smoked or not smoking for >6 months with <10 pack years history (Pack years = (cigarettes per day smoked/20) x number of years smoked))
- •Clinical laboratory tests data obtained at screening meet the following:
- •AST(GOT), ALT(GPT), total-bilirubin: below the upper limit of the normal ranges
- •Normal 12-lead EGC finding at screening; QTc(B) interval <450msec
- •Normal spirometry (FEV1 ≥ 80% of predicted, FEV1/FVC ≥ 70%).
- •Rapid ACTH with normal range at the screening.
- •Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- •Capable of using the novel dry powder inhaler.
排除标准
- •The subject has any clinically relevant abnormality on medical examination, vital sign, clinical laboratory test or medical history at screening in the medical opinion of the investigator or the subject has a medical history that is not considered as eligible for inclusion in this study by the investigator.
- •The subject has an allergy for any drug or idiosyncrasy
- •The subject has an allergy for any drug hypersensitivity to milk protein or the excipients lactose monohydrate and magnesium stearate.
- •T he subject is currently participating in another clinical study or post-marketing study in which the subject is or will be exposed to an investigational or a non-investigational drug or device.
- •The subject has participated in a clinical study with an investigational or a non-investigational drug or device during the previous 4 months.
- •The subject has a history or current conditions of drug abuse or alcoholism.
- •History of regular alcohol consumption exceeding on average, 14 drinks/week (1 drink = 5 ounces (150mL) of wine or 350mL of beer or 1.5 ounces (45mL) of 80 proof distilled spirits) within 6 month of screening.
- •The subject is positive for urine drug at screening.
- •Use of prescription or non-prescription drugs, including CYP3A/PGP inhibitor, vitamins, herbal and dietary supplements (including St John'sWort) within 14 days prior to the first dose of study medication.
- •The subject has a known allergy or hypersensitivity to corticosteroids.
- •The subject has a known allergy or hypersensitivity to synthetic ACTH
- •The subject has a history of asthma in childhood or respiratory disorder.
- •The subject is a permanent (or occasional during the study) night-shift worker*.
- •* Permanent night shift worker defines as the person who has been continuing life that gets up after 12:00 day time and eats supper after 0:00 midnight for seven days or more usually.
- •The subject is positive for syphilis, HBs antigen, HCV antibody, HIV antibody, HTLV-1 antibody.
- •The subject has donated a unit of blood ">400mL" within the previous 4 months or ">200mL" within the previous 1 month.
研究组 & 干预措施
arm 1
Experimental
In Arm 1 subjects will receive 200, 400 or 800 microgram of powdered inhalation of GW685698X once daily for 7 days from Day 5 to Day 11.
干预措施: GW685698X (Drug)
arm 2
Placebo Comparator
In Arm 2 subjects will receive Placebo powdered inhalation once daily for 7 days from Day 5 to Day 11.
干预措施: Placebo (Drug)
结局指标
主要结局
PD: serum cortisol
safety: adverse events, vital sign, ECGs, and clinical laboratory test
PK： Cmax, tmax and AUC(0-t)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).Rhinitis, Allergic, PerennialNCT00103454GlaxoSmithKline288
已完成
3 期
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)Rhinitis, Allergic, PerennialNCT00289198GlaxoSmithKline301
已完成
3 期
Study Of Adults And Adolescents With Vasomotor RhinitisRhinitis, VasomotorNCT00117325GlaxoSmithKline352
已完成
3 期
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor RhinitisVasomotor RhinitisRhinitis, VasomotorNCT00118703GlaxoSmithKline350
已完成
1 期
Phase I Study of GW642444M in Healthy Japanese Male SubjectsPulmonary Disease, Chronic ObstructiveNCT00964249GlaxoSmithKline32